Your browser doesn't support javascript.
loading
Mechanism of action of non-coding RNA in sorafenib resistance in hepatocellular carcinoma / 临床肝胆病杂志
Journal of Clinical Hepatology ; (12): 699-703, 2021.
Article in Chinese | WPRIM | ID: wpr-873820
ABSTRACT
Sorafenib, as the first-line treatment drug for advanced hepatocellular carcinoma (HCC), can effectively improve the prognosis of patients with HCC, but sorafenib resistance has become a major obstacle to the therapeutic outcome of HCC. Recent studies have shown that non-coding RNA plays a key role in sorafenib resistance in HCC. This article summarizes that non-coding RNA regulates the sensitivity of HCC to sorafenib by inducing the autophagy of hepatoma cells, promoting the proliferation of liver cancer stem cells, promoting the EMT process of hepatoma cells, inhibiting the apoptosis of hepatoma cells, and regulating the microenvironment of liver cancer tissue. It is pointed out that the molecular mechanism of non-coding RNA in regulating sorafenib resistance in HCC has potential clinical significance in overcoming sorafenib resistance in HCC.

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Journal of Clinical Hepatology Year: 2021 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Journal of Clinical Hepatology Year: 2021 Type: Article